Toggle menu

PREFER

Start date:
Historic
End date:
June 2014
Co-ordinated by:
Daiichi Sankyo Deutschland GmbH, Munich

Prefer in VTE Prevention of Thromboembolic Events – European Registry in Venous Thromboembolism

 

Aim

To assess the 12 month direct health care resource use and estimated costs following acute first-time (initial) or recurrent VTE

Trial Design

Multi –national, multi-centre, prospective observational disease registry

Chief Investigator

Dr Petra Laeis, Munich

Local PI

Dr. Matt Reed

Local PI

Dr Matt Reed

Consultant, NRS Career Research Fellow & Honorary Reader in Emergency Medicine

More EMERGE Trials

The study with PP100-01 in combination with NAC is designed to determine safety and tolerability of PP100-01 when co-administered with NAC as compared to the 12-hr NAC treatment regime for patients that come to the hospital after an overdose of paracetamol/acetaminophen.

Read more

The POP Trial

A Randomised Open Label Exploratory, Safety and Tolerability Study with PP100-01 in Patients Treated with the 12-hour Regimen of N-Acetylcysteine for Paracetamol/Acetaminophen Overdose

Molecular and cellular analysis of intracranial tumours

Read more

BRAINED

Molecular and cellular analysis of intracranial tumours

Patients commonly present to the Emergency Department with epistaxsis (nose bleed). Standard first aid measures such as applying pressure can often stem bleeding however in more severe cases of epistaxsis further treatment is required.

Read more

NoPac

Novel Use of Tranexamic Acid to Reduce the Need for Nasal Packing